DIRS.INFO The most relevant business & tech news

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ 3-Stock Lunch: TXN, BIIB & CMG
▼ + stars: | 2024-04-24 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3-Stock Lunch: TXN, BIIB & CMGJerry Castellini, Castle Ark co-founder, joins ‘Power Lunch’ to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.

Persons: Jerry Castellini Organizations: BIIB, Texas

☆ Stocks making the biggest moves midday: Tesla, Hilton, Boeing, Mattel and more
▼ + stars: | 2024-04-24 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +4 min

Hilton Worldwide Holdings — The hotel stock climbed 4% on the back of strong first-quarter adjusted earnings and raised full-year guidance. Mattel saw $810 million in revenue during the quarterly period, which was less than the consensus estimate of $832 million. Adjusted earnings per share came in at 61 cents, beating analysts' expectations of 27 cents per share, according to LSEG. Revenue of $757 million was greater than the $739 million analysts anticipated. Sales of Biogen's Alzheimer's drug Leqembi came in at about $19 million for the quarter, surpassing the $11 million analysts had anticipated, per FactSet.

Persons: LSEG, Elon Musk, Tesla, Musk's, Hilton, Mattel, Enphase, Biogen, LSEG ., Leqembi, —, Jesse Pound, Alex Harring, Michelle Fox, Lisa Han Organizations: Boeing, . Old Dominion, Hilton Worldwide Holdings, Texas, Mattel, LSEG, Hasbro, Enphase Energy, Dynamics —, Dynamics, Seagate Technology, Seagate Locations: FactSet, LSEG

☆ Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
▼ + stars: | 2024-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Biogen on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected. Biogen and Eisai 's Leqembi became the first drug found to slow the progression of Alzheimer's disease to win approval in the U.S. in July. Leqembi brought in about $19 million in sales for the quarter, up from the $10 million the drug generated last year. In February, Biogen CEO Chris Viehbacher told reporters that there were around 2,000 patients currently on Leqembi. Adjusting for one-time items, the company reported earnings of $3.67 per share.

Persons: Biogen, Leqembi, FactSet, Chris Viehbacher, LSEG Organizations: LSEG Locations: U.S

☆ Stocks making the biggest moves premarket: Boeing, Tesla, Visa, Airbnb and more
▼ + stars: | 2024-04-24 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Airbnb – The vacation property rental platform added nearly 2% following an upgrade by Mizuho to buy from neutral. Visa — Shares of the payment company rose more than 2% after stronger than expected results for the second fiscal quarter. Texas Instruments posted $1.20 per share on $3.66 billion in revenue, beating analysts' projections of $1.07 and $3.61 billion, respectively, per LSEG. Mattel saw $810 million in revenue during the quarterly period, which was less than the consensus estimate of $832 million. Enphase said to expect second-quarter revenue between $290 million and $330 million, under the consensus forecast of $349 million.

Persons: Mizuho, Elon Musk, Tesla, LSEG, —, Enphase, Alex Harring, Samantha Subin, Jesse Pound, Brian Evans, Yun Li, Sarah Min, Michelle Fox Theobald Organizations: Boeing —, Boeing, Mizuho, Summer Olympics, Visa —, Visa, Revenue, Texas, Sea, Capital, Mattel, LSEG, Enphase Energy

☆ Bond auctions are a bigger deal than usual this week. The first went the way of the bulls
▼ + stars: | 2024-04-23 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Treasury yields dip: In addition to earnings, the other part of the market's gauntlet this week is a trio of huge Treasury auctions. The PMI data was softer than expected, confirming signs of the economic "brown shoots" that Jim Cramer has recently been flagging. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Jim Cramer's Organizations: CNBC, Nasdaq, Dow Jones, Treasury, P Global, PMI, Federal, Amazon, Foods, Apple, Developers, Tesla, Enphase, Texas, Boeing, Boston Scientific, Otis Worldwide, Jim Cramer's Charitable Locations: Enphase Energy, Humana

☆ 6 portfolio stock earnings and the Fed's favorite inflation gauge dominate the week ahead
▼ + stars: | 2024-04-20 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

The Nasdaq sank 2% on Friday as Netflix dropped nearly 11% post-earnings and Club stock Nvidia fell 10%, entering bear market territory but still up more than 50% in 2024. Following a much stronger-than-expected March retail sales report last month, fresh economic data and six Club stock earnings will take center stage in the week ahead. While lower rates may help stock multiples, that is not a sustainable path to higher equity prices over time. Earnings : The latest quarterly reporting season is starting to ramp into high gear with six Club names set to report next week. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Dow, Jerome Powell, Jim Cramer, Mark, Meta, Bing, Ford, Vimal, Lockheed Martin, Clark, Philip Morris, Sherwin, Williams, Baker Hughes, Lam, Northrop, Dr Pepper, CARR, Edwards Lifesciences, Jim Cramer's, Jim, Michael M Organizations: Nasdaq, Netflix, Nvidia, Dow Jones, Federal, Fed, Hamas, Gross, Google, Reality Labs, General Motors, Honeywell, Microsoft, Verizon Communications, Albertsons Companies, SAP, Cadence Design Systems, United Parcel Service, General Electric, GE, PepsiCo, Lockheed, Spotify Technology, RTX Corporation, JetBlue Airways, Halliburton, HAL, Philip Morris International, Quest Diagnostics, Texas Instruments, Seagate Technology, Mattel, Veralto Corporation, Boeing, General Dynamics, Boston, Hilton, Fisher, Otis Worldwide, IBM, Grill, Viking Therapeutics, Lam Research, Whirlpool, WM, Honeywell International, Royal Caribbean Cruises, American Airlines, Altria, Newmont, Caterpillar, Southwest Airlines, Myers Squibb, AstraZeneca, Mobileye, Northrop Grumman, CNBC, Comcast, Merck, Dow Inc, Carrier Global, Union Pacific, Intel, Western, Mobile, L3Harris Technologies, Exxon Mobil, Chevron, Colgate, Palmolive, HCA Healthcare, Charter Communications, Newell Brands, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: Israel, Iran, Ukraine, destocking, China, Cleveland, Freeport, McMoRan, Kimberly, Masco, Bristol, New York City

☆ Loads of analysts cut their price targets on these 10 stocks ahead of earnings
▼ + stars: | 2024-04-18 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Analysts have lowered their expectations on several global stocks this week by cutting their price targets. The list of stocks includes auto stocks Tesla , Rivian and Aptiv , pharmaceutical firms Biogen and Novartis , energy companies EQT Corp and TotalEnergies , airline Deutsche Lufthansa and aerospace firm Boeing , and fast food giant McDonald's . The price target changes come ahead of the next earnings season covering the first quarter of this year. CNBC Pro screened for global stocks in the MSCI World index that have received price target downgrades over the past seven days and are yet to report earnings. Tesla Wall Street analysts from 15 firms downgraded their 12-month price targets for Tesla over the past week.

Persons: Elon Musk, Tesla's, Tesla, Stifel Nicholas, Johannes Braun, Marc Zeck, Samantha Subin, Michael Bloom Organizations: Novartis, EQT Corp, Deutsche Lufthansa, Boeing, CNBC Pro, Barclays, Lufthansa Locations: Stifel

☆ These stocks were oversold during this week's sell-off and could be due for a bounce
▼ + stars: | 2024-04-05 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

We used the CNBC Pro Stock Screener Tool to identify companies that are oversold based on their 14-day relative strength index. The stock is slightly oversold with a 14-day RSI reading of 24.52. Biopharmaceutical firm Biogen also made the list, with a 14-day RSI reading of 29.71. BIIB YTD mountain Biogen stock. Other oversold stocks on the list include Starbucks and Nike .

Persons: McDonald's, Krispy Kreme, Biogen, Wall, Baird, Brian P, Skorney Organizations: Dow Jones Industrial, Federal Reserve, CNBC, Israel, Starbucks, Nike Locations: Latin America

☆ Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
▼ + stars: | 2024-03-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly said Friday that the Food and Drug Administration has pushed back its approval decision deadline for the drugmaker's experimental Alzheimer's treatment donanemab in a surprise move. The agency plans to call a last-minute meeting of its outside advisors to further review the treatment's safety and efficacy in a late-stage trial, Eli Lilly said. It's another setback for Eli Lilly, which is racing to compete with Biogen and Eisai. In 2021, the FDA approved an earlier, ill-fated Alzheimer's drug called Aduhelm from Biogen and Eisai, despite a negative recommendation from the agency's advisory panel.

Persons: Eli Lilly, Eli Lilly's, Leqembi, Anne White Organizations: and Drug Administration, FDA Locations: Indianapolis , Indiana, Biogen

☆ Three-Stock Lunch: Biogen, DocuSign & Gap
▼ + stars: | 2024-03-08 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThree-Stock Lunch: Biogen, DocuSign & GapGina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks, including Biogen, DocuSign and Gap.

Persons: Gina Sanchez Organizations: Lido Advisors

☆ With the Nasdaq at record highs, these are the benchmark's most beloved stocks that are expected to rally
▼ + stars: | 2024-03-01 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Even as the Nasdaq Composite is surging to new highs, investors can still find stocks within the index that have room to run. These stocks have a consensus buy rating from analysts and have an upside of 20% or more from their average price targets. Analysts have a consensus buy rating on both stocks, and think AstraZeneca could rally more than 26%, while Biogen could jump roughly 40%. Bank of America last month reiterated its buy rating on Baker Hughes. Twenty-two of the 27 analysts polled by LSEG rate the stock a buy or strong buy, and the average price target suggests 35% upside from here.

Persons: Biogen, Wells, Baker Hughes, Saurabh Pant Organizations: Nasdaq, CNBC, Stock, AstraZeneca, Warner Bros, Biotechnology, Biogen, Deutsche Bank, Analysts, Moderna, HSBC, Discovery, Bank of America, CCS, " Bank of America

☆ This sector offers defensive and growth properties – along with some portfolio income
▼ + stars: | 2024-02-26 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +6 min

The health-care sector of the S & P 500 is up about 8% year to date, marking a sharp comeback from a largely flat 2023. Even as health care is making a comeback this year, investors shouldn't forget its defensive attributes. Back in 2022, when the S & P 500 fell 19.4%, the health-care sector slipped only 3.5% "When markets are challenged, health care can be a good place to be," Lyons added. Some of them speak to the growth aspects of health care and why you can play offense." Merger activity is another driver of growth in health care, as large pharmaceutical companies snap up nimble biotech firms that are at the forefront of developing treatments.

Persons: Dan Lyons, Janus Henderson, shouldn't, Lyons, ImmunoGen, Seamus Fernandez, Sotatercept, Cigna, Cantor Fitzgerald, Sarah James, Fred Imbert Organizations: Big Tech, . Healthcare, Janus, Janus Henderson Investors, U.S . Food, Drug Administration's Center, Drug, Research, FDA, Esai, Pharmaceuticals, CNBC Pro, Merck, Abbott Laboratories, AbbVie, CVS Health Locations: U.S

☆ Carl Icahn gets two seats on JetBlue’s board. Here’s how he may help build value
▼ + stars: | 2024-02-17 | by ( Kenneth Squire | ) www.cnbc.com time to read: +5 min

Activist Commentary: Carl Icahn is the grandfather of shareholder activism and a true pioneer of the strategy. While Carl Icahn is not slowing down at all, in October 2020, he reached an agreement with his son Brett Icahn to rejoin the firm as the eventual successor. Carl Icahn is the quintessential, iconic corporate governance investor. On Jan. 19, Carl Icahn started acquiring his position. On Feb. 12, her first day in her new post, she had a Carl Icahn 13D on her desk.

Persons: Carl Icahn, Brett Icahn, Brett, hasn't, Carl, Sargon, Joanna Geraghty, Carl Icahn 13D, Icahn, Robin Hayes, Geraghty, Hayes, Ken Squire Organizations: Apple, Netflix, Forest Labs, JetBlue, Spirit, Investors, U.S, Transportation Department, 13D Locations: Icahn, Delta, United

☆ Pharma and rideshare providers are among most overbought S&P 500 stocks this week
▼ + stars: | 2024-02-16 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

Despite the market's lack of direction this week, investors nonetheless poured into some specific stocks, pushing them into overbought territory. The RSI, which measures the magnitude and speed of price moves, is a popular yardstick used to evaluate whether shares are overbought or oversold. A stock with a 14-day RSI above 70 is considered overbought, signaling a possible selling opportunity. Biogen is another stock on the list that took a sizable drop this week, with shares tumbling more than 7%. But Wall Street anticipates a turnaround, with the consensus price target reflecting the potential for upside of more than 38%, according to FactSet.

Persons: Eli Lilly, Tesla, Morgan Stanley, Terence Flynn, FactSet, Uber, Stephen Bersey, Bersey Organizations: Dow Jones, Nasdaq, Federal Reserve, CNBC, RSI, pharma, Traders, Uber, Technologies, HSBC Locations: Thursday's, Biogen

☆ What Eli Lilly investors can learn from the slow launch of a competitor's drug
▼ + stars: | 2024-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. The FDA's decision on Lilly's drug, known as donanemab, is expected by the end of March. In the meantime, Eli Lilly's diabetes and obesity drugs, the heart of our investment thesis, should continue to fuel the lion's share of the company's topline growth. About 2,000 patients are currently taking Leqembi, Biogen said Tuesday, up from 800 at the time of the company's third-quarter report in November. LLY YTD mountain Eli Lilly's stock performance so far in 2024.

Persons: Eli Lilly, drugmaker Biogen, Eli Lilly's, —, Lilly, Biogen, Japan's, Chris Viehbacher, Viehbacher, Morgan Stanley, Lilly's, Donanemab, Mounjaro, Jim Cramer, Leqembi, Jim Cramer's, Jim Organizations: Food and Drug Administration, Drug Administration, Alzheimer's Association, FDA, Club, GE Healthcare, FactSet, Pharmaceutical, CNBC Locations: Indianapolis

☆ Here are Wednesday's biggest analyst calls: Tesla, Nvidia, Arm, Citi, Walmart, First Solar, Ulta, GE & more
▼ + stars: | 2024-02-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

UBS downgrades Waste Management to neutral from buy UBS said the trash company has a "lofty" valuation. Citi reiterates Nvidia as buy Citi said its standing by its buy rating heading into earnings next week. " UBS upgrades HF Sinclair to buy from neutral UBS said the refiner is underappreciated. UBS upgrades Huntington Bancshares to buy from neutral UBS said it sees "strong strategic positioning" for the regional bank. Citi downgrades GlobalFoundries to neutral from buy Citi downgraded the semi company following earnings on Tuesday.

Persons: Wells, Redburn, Morgan Stanley, Tesla, it's, Piper Sandler, Piper, Jane Fraser's, Q, BRKRs, BRKR, DINO, D.A, Davidson downgrades Airbnb, Evercore, GlobalFoundries, Bernstein, Wingstop Organizations: Wells, RBC, Enphase Energy, Shoals Technologies, SolarEdge Technologies, UBS downgrades Waste Management, UBS, Citi, Nvidia, JPMorgan, Sinclair, diesel, Deutsche Bank, General, Deutsche, GE, ABNB, ABNB's, Walmart, ISI, Huntington, HSBC, Palantir, HP, Bank of America, of America, Design Systems, Rivals Locations: EBITDA

The firm downgraded the cosmetics stock to hold from buy but maintained $530 per share price target. The firm maintained a neutral rating alongside a $13 per share price target, implying nearly 10% upside ahead. The firm is standing by an underperform rating on Robinhood stock with a $12 per share price target. HSBC downgraded the software stock to hold but maintained its $22 per share price target. First Solar shares have lagged in 2024, losing 11.6% amid concern that Federal Reserve rate cuts may not arrive until later than anticipated.

Persons: Ulta, Anthony Chukumba, Chukumba, Brian Evans, Christopher Danely, — Brian Evans, Robinhood's, Robinhood, LSEG, JPMorgan's Kenneth Worthington, Goldman Sachs, Will Nance, America's Craig Siegenthaler, Wells, Biogen, Mohit Bansal, Stephen Bersey, Christopher Dendrinos, Dendrinos, Fred Imbert Organizations: CNBC, U.S, Wednesday, RBC, HSBC, Palantir, Citi, Revenue, Bank, America's, Technologies, RBC Capital Markets, Enphase Energy, Shoals Technologies Locations: 2024e, Tuesday's, U.S

☆ Stocks making the biggest moves premarket: JetBlue Airways, Arista Networks, Tripadvisor and more
▼ + stars: | 2024-02-13 | by ( Samantha Subin | ) www.cnbc.com time to read: +5 min

Arista Networks — The computer networking stock dropped more than 7% even after the company topped fourth-quarter estimates. Arista Networks said it expected first-quarter revenue to range between $1.52 billion and $1.56 billion versus an estimate of $1.53 billion. Revenue of $2.14 billion was greater than the $2.08 billion expected by analysts polled by FactSet. For the current period, the company expected earnings to range between $130 million and $150 million versus a $174 million estimate. Molson Coors Beverage — Shares added nearly 3% after the beer maker posted a fourth-quarter earnings beat.

Persons: Carl Icahn, Goldman Sachs, Tripadvisor, Datadog, LSEG, ZoomInfo, Tim Hortons, Burger King, BTIG, Hakyung Kim, Alex Harring, Fred Imbert, Sarah Min, Michelle Fox Organizations: JetBlue Airways —, JetBlue Airways, Arista Networks, Revenue, Hasbro, LSEG, FactSet, ZoomInfo Technologies, Cadence, Design Systems, Lattice Semiconductor, Restaurant, Molson Coors Beverage

☆ Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
▼ + stars: | 2024-02-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. Revenue from multiple sclerosis products fell 8% to $1.17 billion as the therapies face competition from cheaper generics. Adjusting for one-time items, the company reported $2.95 per share. But the company expects its pharmaceutical revenue, which includes product revenue and its 50% share of Leqembi sales, to be flat this year compared to 2023.

Persons: Biogen, LSEG, Biogen's, Leqembi Organizations: LSEG, Biogen, Food and Drug, Reata Pharmaceuticals, FDA Locations: U.S

☆ Stocks making the biggest moves midday: JetBlue Airways, Shopify, Biogen and more
▼ + stars: | 2024-02-13 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

Shopify — The e-commerce company saw shares slide more than 10% after it gave a mixed forecast for the current quarter. The company did beat fourth-quarter earnings and revenue estimates. Arista Networks — The computer networking stock fell 4% despite topping fourth-quarter estimates. Marriott International — The hotel chain stock declined 5.7% after missing fourth-quarter revenue estimates. Biogen — The biotechnology stock slumped more than 6% after missing Wall Street's fourth-quarter estimates as revenue and profit declined from a year ago.

Persons: WK Kellogg, Shopify, Goldman Sachs, Marriott's, ZoomInfo, Carl Icahn, Wall, Tripadvisor, Horton, Lennar, Bruker, Microstrategy, CleanSpark, —, Macheel, Samantha Subin, Yun Li, Sarah Min, Alex Harring Organizations: Arista Networks, Marriott, ZoomInfo, —, LSEG, JetBlue Airways —, Hasbro, &, Toll, Cadence, Systems, Cadence Design Systems, Miners, Iris Energy

☆ 5 things next week that could determine if Wall Street's winning streak continues
▼ + stars: | 2024-02-10 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Wall Street wrapped up another positive week, with the S & P 500 closing Friday above 5,000 for the first time ever. It was a pretty light week in terms of economic data releases, though we did get a favorable ISM Services number on Monday. Things will pick up next week with several closely watched macroeconomic updates, including two key government inflation reports. While no Club earnings are scheduled to report earnings in the week ahead, 61 companies in the S & P 500 will deliver their latest quarterly results. Consumer inflation: The main event of the week will come on Tuesday when the January consumer price index (CPI) is released.

Persons: Estee Lauder, Eli Lilly, Price, Bausch, Trimble, Krispy Kreme, Topgolf, Kraft Heinz, Martin Marietta, Owens Corning, WEN, Jim Cramer's, Jim Cramer, Jim, Spencer Platt Organizations: Nasdaq, Club, GE Healthcare, DuPont, Linde, Ford, Disney, Wynn Resorts, CPI, PPI, Palo Alto Networks, Nvidia, Bausch Health, Arista Networks, WM, Cadence Design Systems, ZoomInfo Technologies, Avis Budget, Brighthouse, Goodyear Tire &, Vornado Realty, Marriott International, Hasbro, Restaurant Brands, Molson Coors Beverage, Holdings, MGM Resorts, MGM, Akamai Technologies, American International Group, AIG, Topgolf Callaway Brands, CME Group, Sony, SONY, Blackstone Mortgage Trust, Martin Marietta Materials, Ryder, Occidental Petroleum, Cisco Systems, Deere, Penn Entertainment, Southern Company, Coinbase, Trade, Materials, Rand, Texas, Housing, Jim Cramer's Charitable, CNBC, New York Stock Exchange, Getty Locations: Albemarle, ALB, Ingersoll, New York City

☆ The S&P 500 will try to maintain its momentum next week after breaching 5,000, with key inflation data, earnings on deck
▼ + stars: | 2024-02-09 | by ( Sarah Min | ) www.cnbc.com time to read: +9 min

The S & P 500 broke past 5,000 for the first time ever this week, but investors will see if the momentum can stick in the week ahead with more inflation data and earnings results on deck. On Friday, both the S & P 500 and the Nasdaq Composite were headed for their fifth straight week of gains, and their 14th winning week in 15. FactSet data shows S & P 500 earnings are tracking to have risen 2.8% in the fourth quarter, which would be a second straight quarter of earnings growth, and some expect that positive momentum will remain intact in the weeks ahead. A cooler-than-expected print has the potential to be greeted with enthusiasm, sending the S & P 500 even higher. The S & P 500 is up by 5% this year, with Nvidia higher by more than 40%.

Persons: Jeremy Siegel, CNBC's, Siegel, Karim El Nokali, we've, Tony Welch, Dow, SignatureFD's Welch, there's, Welch, Russell, Jason Hunter, that's, Hunter, Matt Kishlansky, Biogen, Kraft Heinz, Generac Organizations: Treasury, Wharton Business, Nasdaq, Arista Networks, Marriott International, Occidental Petroleum, Deere, Applied Materials, Dow Jones, Wall, Nvidia, Arm Holdings, JPMorgan, New York Community Bancorp, Federal Reserve, Treasury Budget, Waste, CPI, MGM Resorts International, Akamai Technologies, Howmet Aerospace, Molson Coors Beverage, Hasbro, Price, Index, Philadelphia Fed, Retail, Manufacturing, Housing, PPI Locations: SignatureFD, U.S, Long, GenTrust, Albemarle, NAHB, Michigan

☆ Exclusive-Eisai Expects 1,500 Alzheimer's Patients in China Launch, Sees ‘Huge’ Growth
▼ + stars: | 2024-02-04 | by ( Feb. | At P.M. | ) www.usnews.com time to read: +5 min

“China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer’s disease for Eisai,” a company spokesperson said. “The potential growth for Leqembi in China is huge.”Eli Lilly, which is developing a similar treatment called donanemab, told Reuters it has filed for approval in China. The Indianapolis-based company is now testing its drug in a 1,500-person trial with volunteers in China, Taiwan, South Korea and the EU, a spokesperson said. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Once on treatment, suitable patients undergo a series of MRI scans to monitor for potentially fatal swelling and bleeding in the brain.

Persons: Julie Steenhuysen, Andrew Silver CHICAGO, ” Eli Lilly, Biogen, Liu Zhou, Eisai, ”, Hidemaru Yamaguchi, Soeren Mattke, Mattke, Andrew Silver, Caroline Humer, Bill Berkrot Organizations: Reuters, EU, Leqembi, Guangdong Medical University, ” Citi, Psychiatry, Siemens Healthineers, University of Southern, University of Southern California Brain Health Locations: SHANGHAI, China, ”, Leqembi, The Indianapolis, Taiwan, South Korea, Eisai, United States, Japan, Europe, U.S, University of Southern California, Chicago, Shanghai

☆ Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
▼ + stars: | 2024-01-31 | by ( Rebecca Robbins | More About Rebecca Robbins | ) www.nytimes.com time to read: +1 min

The drug maker Biogen said on Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer’s drug that had provoked fierce criticism of the company and regulators after it was approved based on weak evidence that it would help patients. The company will also stop a clinical trial that the Food and Drug Administration had ordered to confirm whether the drug is effective in slowing the progression of Alzheimer’s disease. Biogen’s decision closes out a yearslong saga that generated outrage and eroded trust in the regulatory process for bringing new medicines to market. adviser called the approval of the drug perhaps “the worst approval decision that the F.D.A. has made that I can remember.” A congressional inquiry later found that the F.D.A.’s process for approving Aduhelm was “rife with irregularities” and involved “lapses in protocol,” including unusually close collaboration with Biogen.

Persons: Biogen, Aduhelm Organizations: and Drug Administration

Search resuls for: "Biogen"

25 mentions found